282 related articles for article (PubMed ID: 1281676)
1. Differential oncolytic effect of NK-enriched subsets in long-term interleukin-2 cultures.
Fuchshuber PR; Lotzová E
Lymphokine Cytokine Res; 1992 Oct; 11(5):271-6. PubMed ID: 1281676
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.
Fuchshuber PR; Lotzová E; Pollock RE
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):51-9. PubMed ID: 1651770
[TBL] [Abstract][Full Text] [Related]
3. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.
Gaddy J; Broxmeyer HE
Cell Immunol; 1997 Sep; 180(2):132-42. PubMed ID: 9341743
[TBL] [Abstract][Full Text] [Related]
4. The presence and cytotoxicity of CD16+ CD2- subset from PBL and NK cells in long-term IL-2 cultures enhanced by Prothymosin-alpha.
Cordero OJ; Sarandeses C; López-Rodríguez JL; Nogueira M
Immunopharmacology; 1995 Apr; 29(3):215-23. PubMed ID: 7542644
[TBL] [Abstract][Full Text] [Related]
5. Role of CD16 (Fc receptor III) and interleukin-2 in the reactivation of natural killer cells after inhibitory target cell contact.
Heiskala M; Ståhls A; Seppälä I; Timonen T
Nat Immun Cell Growth Regul; 1991; 10(5):265-77. PubMed ID: 1836835
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity.
Hu PF; Hultin LE; Hultin P; Hausner MA; Hirji K; Jewett A; Bonavida B; Detels R; Giorgi JV
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):331-40. PubMed ID: 7552495
[TBL] [Abstract][Full Text] [Related]
7. Effect of interleukin-12 on antitumor activity of human umbilical cord blood and bone marrow cytotoxic cells.
Condiotti R; Nagler A
Exp Hematol; 1998 Jul; 26(7):571-9. PubMed ID: 9657131
[TBL] [Abstract][Full Text] [Related]
8. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
Carson WE; Fehniger TA; Caligiuri MA
Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-7 selectively enhances natural kill cytotoxicity mediated by the CD56bright natural killer subpopulation.
Dadmarz R; Bockstoce DC; Golub SH
Lymphokine Cytokine Res; 1994 Dec; 13(6):349-57. PubMed ID: 7535569
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
12. Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors.
Lotzová E; Savary CA; Champlin RE
J Immunol; 1993 Jun; 150(12):5263-9. PubMed ID: 7685792
[TBL] [Abstract][Full Text] [Related]
13. A novel functional cell surface dimer (Kp43) expressed by natural killer cells and T cell receptor-gamma/delta+ T lymphocytes. I. Inhibition of the IL-2-dependent proliferation by anti-Kp43 monoclonal antibody.
Aramburu J; Balboa MA; Ramírez A; Silva A; Acevedo A; Sánchez-Madrid F; De Landázuri MO; López-Botet M
J Immunol; 1990 Apr; 144(8):3238-47. PubMed ID: 1691231
[TBL] [Abstract][Full Text] [Related]
14. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL
J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
[TBL] [Abstract][Full Text] [Related]
17. A novel functional cell surface dimer (Kp43) expressed by natural killer cells and gamma/delta TCR+ T lymphocytes. II. Modulation of natural killer cytotoxicity by anti-Kp43 monoclonal antibody.
Aramburu J; Balboa MA; Izquierdo M; López-Botet M
J Immunol; 1991 Jul; 147(2):714-21. PubMed ID: 1830071
[TBL] [Abstract][Full Text] [Related]
18. Generation of a lipid-like cytotoxin from human CD16+ natural killer cells.
Cosentino LM; Cathcart MK
Cancer Res; 1989 Dec; 49(23):6662-9. PubMed ID: 2531033
[TBL] [Abstract][Full Text] [Related]
19. Phenotypically and functionally distinct subsets of natural killer cells in human PBMCs.
Fan YY; Yang BY; Wu CY
Cell Biol Int; 2008 Feb; 32(2):188-97. PubMed ID: 17920947
[TBL] [Abstract][Full Text] [Related]
20. A subset of CD16-natural killer cells without antibody-dependent cellular cytotoxicity function.
Schubert J; Heiken H; Jacobs R; Delany P; Witte T; Schmidt RE
Nat Immun Cell Growth Regul; 1990; 9(2):103-11. PubMed ID: 2141105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
